Inaugurating the International Liver Cancer Association:

ILCA’s First Annual Conference
5 - 7 October 2007
Gran Hotel Princesa Sofia, Barcelona-Spain

Convening a community dedicated to advancing research in the pathogenesis, prevention and treatment of liver cancer

www.ilca-online.org
An invitation from ILCA’s President and Executive Secretary

On behalf of the recently founded International Liver Cancer Association (ILCA), it is our pleasure to invite you to attend our very first Annual Conference that not only marks the launch of an insightful new generation of meetings pioneering a transversal approach to liver cancer, but will set the stage and pace for ILCA Annual Conferences to come.

This pre-conference Final Programme provides you with a detailed overview of just some of the many highlights that await ILCA members, friends, colleagues and peers in Barcelona, Spain, 5-7 October.

Powerful reasons for you to attend include the two translationally and clinically focused State of the Art Sessions, to be delivered by Curtis Harris and Masatoshi Makuuchi respectively, as well as our two core Symposia that will deliver cutting edge advancement at the research and treatment levels. Attracting basic researchers, physicians and allied professionals alike, the underlying key symposia themes centre on and around signal transduction pathways in liver tumours and future prospects in clinical outcomes in liver cancer.

The five specially devised General Sessions – consisting of selected findings to be delivered as oral communications - will offer all participants an unparalleled opportunity to update on the latest developments in molecular pathogenesis, cell biology and translational research; clinical trials and treatment research; epidemiology, staging and prognosis; and diagnostic imaging and molecular pathology.

In the hope that this pre-conference Final Programme will draw your attendance to our inaugural ILCA Annual Conference, we consequently look forward to welcoming you to Barcelona for what promises to be an unforgettable meeting.

Jordi Bruix, M.D.
President

Josep M. Llovet, M.D.
Executive Secretary
# Programme at a Glance

## Friday, 5 October

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
</table>
| 11.30 - 13.15 | Industry Symposium (Biocompatibles)  
TACE in HCC: A multi-disciplinary overview                                                   | Lleida/Tarragona |
| 13.15 - 13.30 | Opening Ceremony                                                                         | Lleida/Tarragona |
| 13.30 - 15.00 | General Session 1: Clinical trials and treatment (Curative)                               | Lleida/Tarragona |
| 15.00 - 16.00 | The Translational Lecture: Chronic inflammation and cancer development  
Speaker: Curtis Harris, Bethesda (USA)                                                   | Lleida/Tarragona |
| 16.00 - 16.30 | Coffee Break                                                                              | Sitges/Rosas & Baleares |
| 16.30 - 18.00 | General Session 2: Molecular pathogenesis (Genomics)                                     | Lleida/Tarragona |
| 18.00 - 19.30 | Industry Symposium (Bayer Schering Pharma)  
Recent advances with targeted therapies: a new era in the management of hepatocellular carcinoma | Lleida/Tarragona |
| 19.30 - 20.30 | Welcome Reception                                                                         | Sitges/Rosas & Baleares |

## Saturday, 6 October

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00 - 10.30</td>
<td>General Session 3: Molecular pathogenesis (Signalling and novel targets)</td>
<td>Lleida/Tarragona</td>
</tr>
<tr>
<td>10.30 - 11.00</td>
<td>Coffee Break</td>
<td>Sitges/Rosas &amp; Baleares</td>
</tr>
<tr>
<td>11.00 - 13.00</td>
<td>Symposium: Future prospects in clinical research in HCC</td>
<td>Lleida/Tarragona</td>
</tr>
</tbody>
</table>
| 13.00 - 15.00 | Industry Symposium (Bracco)  
Focal liver lesions - The key role of contrast-enhanced UltraSound (CEUS) modality for diagnosis and early assessment of treatment efficacy | Lleida/Tarragona |
| 15.00 - 16.30 | Business Meetings for ILCA Members                                                         | Lleida/Tarragona |
| 16.30 - 17.00 | Coffee Break                                                                              | Sitges/Rosas & Baleares |
| 17.00 - 18.30 | General Session 4: Clinical trials and treatment (RCTs and new therapies)                 | Lleida/Tarragona |
Sunday, 7 October

08.30 - 09.00  IARC's research agenda for combating liver cancer worldwide  Lleida/Tarragona
09.00 - 11.00  Symposium: Signal transduction pathways in liver tumors  Lleida/Tarragona
11.00 - 11.30  Coffee Break  Sitges/Rosas & Balearics
11.30 - 12.30  The Clinical Lecture: Past, present and future of surgical management of HCC  
                 Speaker: Masatoshi Makuuchi, Tokyo (Japan)  Lleida/Tarragona
12.30 - 14.00  General Session 5: Diagnosis, staging and prognosis  Lleida/Tarragona
14.00 - 14.10  Closing Remarks  Lleida/Tarragona

To register, please visit www.ilca-online.org

Participants will be able to visit the Poster Exhibition on Friday, 5 October and Saturday, 6 October, from 09.00 - 18.00. A list of posters on display can be found on page 16.
### Scientific Programme

#### Friday, 5 October

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.30 - 13.15</td>
<td>Industry Symposium (Biocompatibles) TACE in HCC: A multi-disciplinary overview</td>
<td>Lleida/Tarragona</td>
</tr>
<tr>
<td></td>
<td>For further details see pages 20/21 - Industry Symposia Highlights</td>
<td></td>
</tr>
<tr>
<td>13.15 - 13.30</td>
<td>Opening Ceremony</td>
<td>Lleida/Tarragona</td>
</tr>
<tr>
<td>13.30 - 15.00</td>
<td>General Session 1: Clinical trials and treatment (Curative)</td>
<td>Lleida/Tarragona</td>
</tr>
<tr>
<td></td>
<td>Chairs: M. Colombo (Italy), M. Schwartz (USA)</td>
<td></td>
</tr>
</tbody>
</table>
| 13.30 - 13.45 | **O-001** Living donor liver transplantation for hepatocellular carcinoma; experience with 653 cases in Japan  
Authors: Tsuyoshi Shimamura¹, H Furukawa¹, T Suzuki¹, M Taniguchi¹, K Yamashita¹, T Kamiyama¹, M Matsushita¹, S Todo¹  
¹Division of Organ Transplantation, Hokkaido University Hospital, Sapporo, Japan |                    |
| 13.45 - 14.00 | **O-002** Grading of microvascular invasion by hepatocellular carcinoma treated by hepatic resection  
Authors: Sasan Roayaie¹, Mostafa Gaabour¹, Iris Blume¹, Swan Thung¹, Josep Llovet¹, Myron Schwartz¹  
¹Mount Sinai Liver Cancer Program, Department of Surgery, New York, United States |                    |
| 14.00 - 14.15 | **O-003** Surgical resection for hepatocellular carcinoma with portal vein tumor thrombus  
Authors: Kiyoshi Hasegawa¹, Norihiro Kokudo¹, Hiroshi Imamura¹, Takeaki Ishizawa¹, Yosuke Inoue¹, Michiro Takahashi¹, Taku Aoki¹, Yoshifumi Beck¹, Keiji Sano², Yasuhiko Sugawara², Masatoshi Makuuchi²  
¹Hepato-Biliary-Pancreatic Surgery Division, University of Tokyo,  
²Department of Surgery, Japanese Red Cross Medical Center, Tokyo, Japan |                    |
| 14.15 - 14.30 | **O-004** Liver resection for intrahepatic cholangiocarcinoma                               
Authors: Sven Jonas¹, Armin Thelen¹, Christoph Benckert¹, Enrique Lopez Hänninen², Birgit Rudolph³, Johann Pratschke¹, Peter Neuhaus¹  
¹General, Visceral and Transplantation Surgery, ³Radiology, Charité Campus Virchow Klinikum, ²Pathology, Charité, Berlin, Germany |                    |
14.30 - 14.45

- **O-005** Predictors of dropout from transplant waiting list among patients listed for hepatocellular carcinoma using the UNOS/OPTN database
  
  Authors: Carlos Romero Marrero¹, Jorge Marrero¹, Sherry Fu¹, Veena Thyagarajan¹
  
  ¹Medicine, University of Michigan, Ann Arbor, United States

14.45 - 15.00

- **O-006** Liver transplantation as primary therapy for hepatocellular carcinoma in non-cirrhotic livers
  
  
  ¹University Medical Center Groningen, University of Groningen, Groningen, Netherlands, ², Hôpital Paul Brousse, Villejuif, France, ³, Huddinge Hospital, Huddinge, Sweden, ⁴, Medizinische Hochschule, Hannover, Germany, ⁵, Children’s Memorial Health Institute, Warsaw, Poland, ⁶, Universitätsklinikum Essen, Essen, ⁷, Universitätsklinik Tübingen, Tübingen, Germany, ⁸, Sahlgrenska University Hospital, Gothenburg, Sweden, ⁹, Universitair Ziekenhuis Ghent, Ghent, ¹⁰, Universitaire Ziekenhuizen Leuven, Leuven, Belgium, ¹¹, Hôpital Jean Minjoz, Besançon, ¹², Hôpital de la Conception, Marseille, France, ¹³, Leiden University Medical Center, Leiden, Netherlands, ¹⁴, Hospital Juan Canalejo, La Coruna, Spain, ¹⁵, Universitätskliniken Goettingen, Göttingen, Germany, ¹⁶, Hôpital Hautepierre, Strasbourg, France, ¹⁷, University Hospital Leuven, Leuven, Belgium, ¹⁸, Istituto Nazionale Tumori, Milano, Italy

15.00 - 16.00

The Translational Lecture: Chronic inflammation and cancer development

Lleida/Tarragona

Chair: Gregory J. Gores, Rochester (USA)

Speaker: Curtis Harris, Bethesda (USA)
### General session 2: Molecular pathogenesis (Genomics)

**Chairs:** M.A. Buendia (France), S. Thorgeirsson (USA)

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.30 - 16.45</td>
<td>O-007 A new prognostic subtype of hepatoblastoma defined by specific gene expression profile and genomic aberrations</td>
</tr>
<tr>
<td></td>
<td>Authors: Carolina Armengol*1, Cairo Stefano2, Aurélien de Reyniès3, Emilie Thomas3, Veronique Laithier4, Laurence Brugières5, Marco Pontoglio6, Monique Fabre2, Marie Annick Buendia2</td>
</tr>
<tr>
<td></td>
<td>1Unite d’Oncogenèse et Virologie Moléculaire, 2Unite d’Oncogenèse et Virologie Moléculaire, Institut Pasteur, 3Informatic Department, Ligue Nationale contre le Cancer, Paris, Onco-Hématologie pédiatrique, CHU de Besançon, Besançon, 4Pediatric Department, Institut Gustave Roussy, Villejuif, 5Gene Expression and Disease Unit, Centre National de la Recherche Scientifique (CNRS) FRE 2850, Institut Pasteur, Paris, 6Anatomie et Cytologie Pathologiques, CHU de Bicêtre, Le Kremlin-Bicêtre, France</td>
</tr>
<tr>
<td>16.45 - 17.00</td>
<td>O-008 Expression of stemness gene Bmi-1 in hepatocellular carcinoma</td>
</tr>
<tr>
<td></td>
<td>Author: Michiie Sakamoto*1</td>
</tr>
<tr>
<td></td>
<td>1Pathology, Keio University School of Medicine, Tokyo, Japan</td>
</tr>
<tr>
<td>17.00 - 17.15</td>
<td>O-009 Integrated profiling of DNA and RNA alterations in hepatitis C virus positive hepatocellular carcinomas</td>
</tr>
<tr>
<td></td>
<td>Authors: Derek Chiang*1, Augusto Villaneuva2, Judit Peix2, Philippa Newell2, Elisa Wurmbach2, Diana Donovan2, Rameen Beroukhim1, Gad Getz1, Sasan Roayaie2, Myron Schwartz2, Vincenzo Mazzaferro4, Jordi Bruix3, Samuel Waxman2, Scott Friedman2, Massimo Loda3, Azra Ligon1, Matthew Meyerson3, Josep Llovet2</td>
</tr>
<tr>
<td></td>
<td>1Cancer Program, Broad Institute of Harvard and MIT, Cambridge, 2Mount Sinai Liver Cancer Program, Mount Sinai School of Medicine, New York, 3-Pathology, Brigham and Women’s Hospital, Boston, United States, 4-Digestive Surgery and Liver Transplantation Unit, National Cancer Institute, Milan, Italy, 5-Barcelona Clinic Liver Cancer group, University of Barcelona, Barcelona, Spain</td>
</tr>
<tr>
<td>17.15 - 17.30</td>
<td>O-010 Survival gene signature for hepatocellular carcinoma (HCC) from high-throughput profiling of informative transcriptome in archived paraffin-embedded tissue</td>
</tr>
</tbody>
</table>
Authors: Yujin Hoshida*, Masahiro Kobayashi, Augusto Villanueva, Amy Camargo, Supriya Gupta, Jamie Moore, Matthew J. Wrobel, Jim Lerner, Michael Reich, Jennifer A. Chan, Kenji Ikeda, Masashi Hashimoto, Goro Watanabe, Sasan Roayaie, Myron Schwartz, Swan Thung, Stacey Gabriel, Vincenzo Mazzaferro, Jordi Bruix, Scott Friedman, Hiromitsu Kumada, Josep M. Llovet, Todd R. Golub

1Broad Institute, Massachusetts Institute of Technology and Harvard University, Cambridge, United States, 2Department of Gastroenterology, Toranomon Hospital, Tokyo, Japan, 3Mount Sinai Liver Cancer Program, Mount Sinai School of Medicine, New York, United States, 4National Cancer Institute, Milan, Italy, 5Barcelona Clinic Liver Cancer Group, Hosp Clinic Barcelona, Tokyo, Spain

17.30 - 17.45

• O-011 miRNA expression profiling in benign and malignant liver tumors: correlations with clinical and genetic features
  Authors: Yannick Ladeiro*, Gabrielle Couchy, Jessica Zucman-Rossi
  1CEPH, Inserm U674, Paris, France

17.45 - 18.00

• O-012 A unique metastasis-related microRNA expression signature is a prognostic indicator of survival and recurrence in hepatocellular carcinoma
  Authors: Anuradha Budhu*, Hu-Liang Jia, Marshonna Forgues, Chang-Gong Liu, David Goldstein, Amy Liu, Krista A. Zanetti, Qing-hai Ye, Lun-Xiu Qin, Carlo M. Croce, Zhao-You Tang, Xin W. Wang
  1Laboratory of Human Carcinogenesis, National Cancer Institute, Bethesda, 2Molecular Virology, Immunology, and Medical Genetics and Comprehensive Cancer Center, Ohio State University, Columbus, 3Office of Science and Technology Partnerships, National Cancer Institute, Bethesda, 4EMMS Corporation, EMMS Corporation, Rockville, United States, 5LiverCancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China

18.00 - 19.30

Industry Symposium (Bayer Schering Pharma)
Recent advances with targeted therapies: a new era in the management of hepatocellular carcinoma

For further details see pages 20/21 - Industry Symposia Highlights
Saturday, 6 October

09.00 - 10.30  General Session 3: Molecular pathogenesis (Signalling and novel targets)
               Room: Lleida/Tarragona
               Chairs: J.F. Dufour (Switzerland), M. Ozturk (Turkey)
               
09.00 - 09.15  0-013 Stromal regulation of hepatocarcinogenesis: PDGF receptors as a target for therapy
               Authors: Claudia Mitchell*, Nelson Fausto1, Jean Campbell1, Matthew Yeh1
               1Pathology, University of Washington, Seattle, United States; 2Pathology, University of Washington, Seattle
               
09.15 - 09.30  0-014 Molecular and functional dissection of the insulin-like growth factor (IGF)-II signalling pathway in human hepatocarcinogenesis
               Authors: Kay Breuhahn1, Tanja Nussbaum1, Volker Ehemann1, Eduard Ryschich2, Akmal Khamidjanov1, Peter Schirmacher1, Kai Breuhahn1
               1Institute of Pathology, 2Department of Surgery, University Hospital Heidelberg, Heidelberg, Germany
               
09.30 - 09.45  0-015 Smad interacting protein SIP1 acts as a negative regulator of growth in hepatocellular carcinoma cells
               Authors: Ayca Arslan-Ergul*, Sevgi Bagislar1, Nuri Ozturk1, Serif Senturk1, Mehmet Ozturk1
               1Molecular Biology and Genetics, Bilkent University, Ankara, Turkey; 2Biochemistry and Biophysics Dept., University of North Carolina, Chapel Hill, United States
               
09.45 - 10.00  0-016 Homozygous deletion of p53 induces liver cancer exhibiting
               Authors: André Lechel*, Yvonne Begus*, Peter Schirmacher1, K.Lenhard Rudolph1
               1Gastroenterology, Medical School Hannover, Hannover, Germany; 2Pathology, University of Heidelberg, Heidelberg, Germany
               
10.00 - 10.15  0-017 Integrative genomic analysis of PI3K/Akt/mTOR pathway in hepatocellular carcinoma: clinical outcome implications
               Authors: Augusto Villanueva1, Derek Y. Chiang2, Philippa Newell1, Judit Peix1, Yujin Hoshida2, Stijn Van Laarhoven1, Swan Thung3, Sasan Roayaie4, Clara Alsina5, Isabel Fiel6, Myron Schwartz6, Samuel Waxman6, Jordi Bruix3, Vinzenzo Mazzaferro7, Todd Golub2, Scott L. Friedman1, Matthew Meyerson2, Josep M. Llovet1,5
               1Liver Diseases, Mount Sinai School of Medicine, New York; 2Cancer Program, Broad Institute of MIT and Harvard, Cambridge; 3Pathology, 4Surgical Oncology, Mount Sinai School of Medicine, New York; 5Liver Unit, Hospital Clinic, Barcelona,
14018  Sorafenib inhibits the Raf/MEK/ERK pathway and angiogenesis, induces apoptosis and produces robust efficacy in preclinical models of hepatocellular carcinoma (HCC)

Authors: Scott Wilhelm1, Lila Adnane1, Mark Lynch1

1 Global Scientific Communications Oncology, Bayer Pharmaceuticals Corporation, West Haven, United States

10.15 - 10.30

11.00 - 13.00  Symposium: Future prospects in clinical research in HCC

Chairs: Pierre-A. Clavien, Zurich (Switzerland), Ding-Shinn Chen, Taipei (Taiwan)

- Review of current guidelines for clinical practice and research
  Jordi Bruix, Barcelona (Spain)

- New markers for screening and diagnosis
  Laura Beretta, Seattle (USA)

- Emerging molecular targeted therapies
  Andrew X. Zhu, Boston (USA)

- Principles of trial design in HCC research
  Josep M. Llovet, Barcelona (Spain) - New York (USA)

13.00 - 15.00  Industry Symposium (Bracco)

Focal liver lesions - The key role of contrast-enhanced UltraSound (CEUS) modality for diagnosis and early assessment of treatment efficacy

For further details see pages 20/21 - Industry Symposia Highlights

15.00 - 16.30  Business Meetings for ILCA Members
Saturday, 6 October

17.00 - 18.30 General Session 4: Clinical trials and treatment (RCTs and new therapies)

17.00 - 17.15
- **0-019 Activity of sunitinib in patients with advanced hepatocellular carcinoma (HCC): an international phase II trial**
  Authors: Sandrine Faivre*, Eric Raymond, Jean Y. Douillard, Eveline Boucher, Ho Y. Lim, Jun S. Kim, Francoise Degos, Franca Lanzalone, Maria J. Lechuga, Laurie J. Sherman, Ann-Lee Cheng
  1Service Inter Hospitalier de Cancerologie Bichat-Beaujon, Hopital Beaujon, Clichy,
  2Service Oncologie Medicale, Centre Rene Gauducheau, St-Herblain
  3Hopital Pontchaillou, University Hospital, Rennes, France
  4Division of Hematology/Oncology, Samsung Medical Center
  5Guro Hospital, Korea University, Seoul, South Korea
  6Clinical Research Oncology, Pfizer, Milan, Italy
  7Oncology-Medicine Development Center, GlaxoSmithKline, Collegeville, United States
  8Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan

17.15 - 17.30
- **0-020 Long acting octreotide in the treatment of advanced hepatocellular carcinoma and overexpression of somatostatin receptors. A randomized placebo-controlled trial**
  Authors: Dimitrios Dimitroulopoulos*, Dimitrios Xinopoulos, Klisthenis Tsamakidis, Efthimios, Andriotis, Athanasios Zisimopoulos, Aikaterini Fotopoulou, Dimitrios Kipreos, Stamatina Patsavela, Argiro Loukou, Athanasios Bazinis, Dimitra Daskalopoulou, Emmanouil Paraskevas
  1Gastroenterology, 2CT Dpt., Agios Savvas Cancer Hospital, Athens
  3Nuclear Medicine, University of Thrace, Alexandroupolis
  4Radiation Oncology, 5Psychiatry, 6Cytology, Agios Savvas Cancer Hospital, Athens, Greece

17.30 - 17.45
- **0-021 A phase II study of sunitinib in patients with advanced hepatocellular carcinoma**
  Authors: Andrew Zhu*, Dusyhant V. Sahani, Emmanuelle di Tomaso, Dan Duda, Vivek Sindhwani, Sam S. Yoon, Lawrence S. Blaszkowsky, Jeffrey W. Clark, David P. Ryan, Rakesh K. Jain
17.45- 18.00 • O-022 Sorafenib improves survival in hepatocellular carcinoma: results of a phase III randomized placebo-controlled trial
Authors: Jordi Bruix*, Sergio Ricci, Vincenzo Mazzaferro, Philip Hilgard, Jean-Luc Raoult, Armando Santoro, Jean-Frédéric Blanc, Edward Gane, Stefan Zeuzem, Minghua Shan, Marius Moscovici, Dimitris Voliotis, Josep M. Llovet
1. Unidad de cancer hepático, Hospital Clinic i Procinial, Barcelona, Spain, 2. Unità Operativa di Oncologia Medica, Azienda Ospedaliera Universitaria Pisana, Pisa, 3. Unità Operativa Chirurgia Apparato Digerente e Trapianto di Fegato, IRCCS, Milano, Italy, 4. Dept. for Gastroenterology und Hepatology, University Hospital Essen, Essen, Germany, 5. Département d’Oncologie Médicale, Centre Eugène Marquis, RENNES, France, 6. Dipartimento Oncologia Medica e Ematologia, Istituto Clinico Humanitas, Rozzano, Italy, 7. Service d’hépato-gastroentérologie, Hôpital Saint André, BORDEAUX, France, 8. NZ Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand, 9. Abteilung für Innere Medizin, Universitätsklinikum des Saarlandes, Homburg, Germany, 10. Bayer, Pharmaceuticals, West Haven, United States, 11. Bayer, Pharmaceuticals, Viale Certosa, Italy, 12. Bayer, Pharmaceuticals, Wuppertal, Germany, 13. Division of Liver Diseases, Mount Sinai School of Medicine, New York, United States

18.00 - 18.15 • O-023 A randomized trial comparing 3-month vs. 6-month screening for HCC by ultrasonography in cirrhosis
Authors: Michel Beaugrand*, Jean Claude Trinchet, Cooperative group GRETCH
1. Hepatology, Jean Verdier hospital, Bondy, France

18.15 - 18.30 • O-024 Four decades’ studies on hepatocellular carcinoma — from bench to bedside
Author: Zhao-You Tang
1. Liver Surgery, Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China
**Sunday, 7 October**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.30 - 09.00</td>
<td>IARC’s research agenda for combating liver cancer worldwide</td>
<td>Lleida/Tarragona</td>
</tr>
<tr>
<td></td>
<td>Chair: H. El-Serag (USA)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Presenter: P. Hainaut (France)</td>
<td></td>
</tr>
<tr>
<td>09.00 - 11.00</td>
<td>Symposium: Signal transduction pathways in liver tumors</td>
<td>Lleida/Tarragona</td>
</tr>
<tr>
<td></td>
<td>Chairs: Peter Galle, Mainz (Germany), Kazuhiko Koike, Tokyo (Japan)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Signaling pathways in the pathogenesis of HBV and HCV-related HCC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jack R. Wands, Providence (USA)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Telomere shortening, cirrhosis, and cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lenhard Rudolph, Hannover (Germany)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- The wnt canonical pathway in benign and malignant liver tumors</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jessica Zucman-Rossi, Paris (France)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Linking signaling pathways and clinical outcomes in liver cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Snorri Thorgeirsson, Bethesda (USA)</td>
<td></td>
</tr>
<tr>
<td>11.30 - 12.30</td>
<td>The Clinical Lecture: Past, present and future of surgical management of HCC</td>
<td>Lleida/Tarragona</td>
</tr>
<tr>
<td></td>
<td>Chair: Vincenzo Mazzaferro, Milan (Italy)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker: Masatoshi Makuuchi, Tokyo (Japan)</td>
<td></td>
</tr>
<tr>
<td>12.30 - 14.00</td>
<td>General Session 5: Diagnosis, staging and prognosis</td>
<td>Lleida/Tarragona</td>
</tr>
<tr>
<td></td>
<td>Chairs: M. Sherman (Canada), K. Takayasu (Japan)</td>
<td></td>
</tr>
<tr>
<td>12.30 - 12.45</td>
<td>O-025 Outcome and prognostic factors of untreated hepatocellular carcinoma (HCC) on cirrhosis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Authors: Luisa Benvegnu¹, Maurizio Gios¹, Francesca Pasin¹, Annamaria Di Nolfo²,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Paolo Del Poggio³, Gianluudovico Rapaccini⁴, Fabio Farinati⁵, Marco Zoli⁶, Franco Borzio⁷,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Edoardo G. Giannini⁸, Eugenio Caturelli⁹, Alfredo Alberti¹⁰, Mauro Bernardi¹⁰,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Franco Trevisani¹⁰</td>
<td></td>
</tr>
<tr>
<td></td>
<td>¹Dpt. of Clinical and Experimental Medicine, University of Padova, Padova, ²Dpt. Medicine, Hospital,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Seriate, ³Dpt. Medicine, Hospital, Treviglio, ⁴Internal Medicine, University of Roma, Roma, ⁵Dpt.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Surgical and Gastroenterological Science, University of Padova, Padova, ⁶Dpt. Internal Medicine,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>University of Bologna, Bologna, ⁷Dpt. Medicine, Hospital, Milan-⁸Dpt. Internal Medicine, University</td>
<td></td>
</tr>
<tr>
<td></td>
<td>of Genova, Genova, ⁹Dpt. of Gastroenterology, Belcolle Hospital, Viterbo, ¹⁰Dpt. of Gastroenterology,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>University of Bologna, Bologna, Italy</td>
<td></td>
</tr>
</tbody>
</table>
• 0-026 Detection of hypervascular foci in hypovascular borderline lesion upon cirrhotic liver: comparison of dynamic contrast enhanced multi-detector row CT, dynamic gadolinium-enhanced MR, and SPIO-enhanced MR imaging
Authors: Satoshi Kobayashi¹, Rieko Shinmura¹, Osamu Matsui¹, Toshifumi Gabata¹, Junichiro Sanada¹, Wataru Koda¹, Tetsuya Minami¹, Yasuji Ryu¹
¹Radiology, Kanazawa University School of Medicine, Kanazawa, Japan

• 0-027 Vessel invasion of hepatocellular carcinoma: can high risk factors be identified on preoperative CT scan?
Author: Mi-Suk Park¹
¹Department of Diagnostic Radiology, Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea

• 0-028 Clinicopathological study on cholangiolocellular carcinoma suggesting hepatic progenitor cell origin
Authors: Mina Komuta¹, Sara Vander Borght², Raymond Aerts², Masamichi Kojiro³, Tania Roskams¹
¹Pathology, K.U Leuven, ²Abdominal Surgery Section, KU Leuven University Hospitals of Gasthuisberg, Leuven, Belgium, ³Pathology, Kurume University, Kurume, Japan

• 0-029 Sequencing of HVRII and HVRIII of mitochondrial-DNA distincts between disseminated and synchronic hepatocellular carcinoma (HCC)
Authors: Maria Varela¹, Loreto Boix¹, Manel Sole², Alejandro Forner¹, Amelia J. Hessheimer¹, Jordi Bruix¹
¹BCLC group, Liver Unit, ²Pathology Department, Hospital Clinic, Barcelona, Spain

• 0-030 Loss of heterozygosity at D8S298 is a predictor for long-term survival of patients with TNM stage I of hepatocellular carcinoma
Authors: Lun-Xiu Qin¹, Jin-Zhong Pang¹, Ning Ren¹, Qing-Hai Ye¹, Yin-Kun Liu¹, Zhao-You Tang¹
¹Dept of Liver Surgery, Liver Cancer Institute and Zhongshan Hospital, Fudan University, Shanghai, China
A poster exhibition will take place during the conference. Posters will be on display all day long from 09:00 to 18:00 on Friday, 5 October and Saturday, 6 October in the Sitges, Rosas and Girona rooms of the Gran Hotel Princesa Sofia, venue of the conference.

Posters will be displayed for one day, according to their topic. Top scored posters will be displayed on both days: Friday, 5 October and Saturday, 6 October.

**FRIDAY, 5 OCTOBER**
Topic 1: Molecular pathogenesis, cell biology, and translational research

**SATURDAY, 6 OCTOBER**
Topic 2: Epidemiology, staging and prognosis
Topic 3: Diagnostic imaging and molecular pathology
Topic 4: Clinical trials and treatment research
Topic 5: Miscellaneous

### TOP SCORED POSTERS
5 – 6 October 2007

1. Molecular pathogenesis, cell biology and translational research

- P-001 Gene expression profiles reveal common features between reversal of hepatocellular malignancy and cellular senescence
- P-002 Vaccination with dendritic cells transduced with a CD40L-expressing adenovirus and an AFP-encoding adenovirus induces specific inhibition of subcutaneous hepatocellular tumor growth in mice
- P-003 Accelerated orthotopic HCC growth is linked with increased pro-angiogenic and pro-lymphangiogenic factors in liver fibrosis
- P-004 Transarterial chemoembolization of unresectable hepatocellular carcinoma (HCC) with drug eluting beads (DEB), results of an open label study of 82 patients
- P-005 Liver transplantation as rescue therapy for intrahepatic recurrence of hepatocellular carcinoma in non-cirrhotic livers after partial liver resection
- P-006 Expression and function of Wnt5a's tumour suppressor (WT) gene in human hepatocellular carcinoma
- P-007 Gene expression profiling in hepatocellular carcinoma and adenoma: expression of genes in amplified chromosome regions
- P-008 The HDM-2/P53 pathway is regulated by iron status in hepatocytes and human primary monocytes, and HDM-2 genotype affects hepatocellular carcinoma risk during iron overload
- P-009 Expression of MRP1 in HCC is associated with a more aggressive tumour phenotype and can reflect a progenitor cell origin
- P-103 Evolving cytogenic abnormalities in long-term cultures of telemebrane-immortalized human fetal hepatocytes
- P-011 Ras/PI3K/Akt promotes cellular growth by enhancing alternative splicing-mediated inactivation of the KLF6 tumour suppressor in human hepatocellular carcinoma

3. Diagnostic imaging and molecular pathology

- P-012 Diagnosis of hepatocellular carcinoma (HCC) < 20 mm detected during surveillance in cirrhosis. Diagnostic value of dynamic imaging techniques
- P-013 Tenorio hepatocellular carcinoma screening protocol (THSP). Initial North American experience with systematic implementation of American association for study of liver disease (AASLD) hepatic screening and workup guidelines
- P-014 Thorough assessment of portal venous thrombosis in patients with HCC allows appropriate selection of candidates for liver transplantation
- P-015 MDM2 promoter SNP 309 is associated with the presence and earlier onset of hepatocellular carcinoma

5. Miscellaneous

- P-016 Hepatocyte differentiation in cholangiocarcinoma, suggesting hepatic progenitor cell origin
- P-017 Octreotide differentially modifies TNFR1, TNFR2 and TNF alpha in rat Kupffer cells. Possible implications for its antineoplastic effect in hepatocellular carcinoma

### POSTERS
Friday, 5 October 2007

1. Molecular pathogenesis, cell biology and translational research

- P-018 MDM2 SNP309 G allele and p53 mutations are mutually exclusive in human hepatocellular carcinomas
- P-019 Life/death decisions governed by epithelial cell polarity: the case of Fas signalling in hepatocytes
- P-020 Low occurrence of occult HBV in patients with cirrhosis due to HCV with or without HCC
- P-021 HCV and ethanol induce mitosis dysregulation via different intracellular pathways
- P-022 Risk of resection of hepatocellular carcinoma in patients with a metabolic syndrome
- P-023 Significance of the anti-inflammatory factor hemeoxygenase-1 (H0-1) for the function of tumour infiltrating macrophages in human hepatocellular carcinoma
- P-024 Control of hepatocytes adhesion and migration by TGF-beta
- P-025 Lanreotide inhibits pro-fibrotic and pro-inflammatory molecules in rat fibrogenesis with the proliferation/apoptosis balance in a rat model of liver carcinogenesis
- P-026 Analysis of Gypican 3-specific CD4+ T cell responses in hepatocellular carcinoma patients
- P-027 Prostaglandin E2-receptor (EP1-4) antagonism as a novel approach to the treatment of hepatocellular carcinoma (HCC)
- P-028 Newly identified hepatic progenitor cell (oval cell) proliferation and mitochondrial abnormalities are characteristic of the hepatocellular carcinoma and liver injury associated with alpha-1-antitrypsin deficiency in human liver and mouse models
- P-029 Biological significance of the marker DCP or PIVKA-2
- P-030 Candidate HCC biomarkers identified by HepG2 micromass
- P-031 Candidate biomarkers of cirrhosis and HCC identified by serum proteomics in patients with NAFLD
- P-032 Role of c-Met in regulation of liver progenitor cell survival
- P-033 High-resolution single-nucleotide polymorphism array analysis in human hepatocellular cancer (HCC) cell lines reveal new candidate genes
- P-034 Clinicopathological features and predictive factors of survival after complete surgical resection for fibrolamellar hepatocellular carcinoma
- P-035 The forced dimerization of collagen 18 inhibits the Wnt/b-catenin signalling in human hepatocellular carcinomas
- P-036 Miblit and NljaV gene polymorphisms of human MDM2 gene in patients with hepatocellular carcinoma
- P-037 Inhibition of the MAPK/ERK pathway potentiates TGF-beta-induced apoptosis in HepG2 cells: role of oxidative stress
- P-038 Recruitment of genetically engineered endothelial progenitor cells by lentiviral vectors in experimental models with hepatocellular carcinoma
- P-039 EGR-1 is induced by growth factors in HPH and HCC cells in a MKK3/ERK-dependent manner
- P-040 VX2 liver tumour response to intra-arterial infusion of 3-bromopyruvate: sequential assessment by FDG PET/CT imaging
- P-041 Laminin-5 stimulates hepatocellular carcinoma growth through a different function of alpha3beta1 and alpha5beta1 integrins
- P-042 Significance of fibroblast growth factors (FGF) 8, 17, and 18 for hepatocarcinogenesis
P-121 Incidence and risk factors of the hepatocellular carcinoma in the south of Madrid community (Central Spain). A case-control study
P-122 External validation of a new prognostic score predicting recurrence of hepatocellular carcinoma after liver transplantation
P-123 Prognosis of patients with cholangiocarcinoma in an american cohort
P-124 Chemoresoption in hepatocellular carcinoma: is etiology of cirrhosis an independent prognostic factor of survival?

P-121 Incidence and risk factors of the hepatocellular carcinoma in the south of Madrid community (Central Spain). A case-control study
P-122 External validation of a new prognostic score predicting recurrence of hepatocellular carcinoma after liver transplantation
P-123 Prognosis of patients with cholangiocarcinoma in an american cohort
P-124 Chemoresoption in hepatocellular carcinoma: is etiology of cirrhosis an independent prognostic factor of survival?

P-125 Liver iron, HFE gene mutations and hepatocellular carcinoma occurrence in patients with cirrhosis
P-126 Pre-transplant ablation is associated with improved post-transplant survival in HCC patients exceeding uro/MLN criteria
P-127 Liver tumors in patients with Fanci anemia
P-128 Hilar and peripheral cholangiocarcinomas (CCC) share similar clinic-biological characteristics
P-129 Identification of MIR125a gene on chromosome 8p as a candidate metastasis suppressor for human hepatoma B virus-positive hepatocellular carcinoma
P-130 Prospective evaluation of staging systems for hepatocellular carcinoma detected during surveillance of cirrhotic patients
P-131 HIV-infected patients with hepatocellular carcinoma have decreased survival than non-HIV patients adjusted by BCL class
P-132 Hepatocellular carcinoma in patients with autoimmune hepatitis
P-133 Squamous cell carcinoma antigen-1 (SCCA1) polymorphism and liver disease stage in chronic HCV infection
P-134 8 years surveillance program for hepatocellular carcinoma in cirrhotic patients in São Paulo, Brazil
P-135 Hepatitis B past infection and HCV related HCC

3. Diagnostic imaging and molecular pathology
P-136 Clinicopathological and gene expression profiles of macrovascular versus microvascular invasion of hepatocellular carcinoma
P-137 Individual and regional liver sensitivity to radiation assessed by CT portal venous perfusion imaging
P-139 Catheter-directed dosimetry as an adjunct to SIRT
P-140 Evaluation of tumour response after locoregional therapies in hepatocellular carcinoma (HCC) are recid criteria reliable?
P-141 Improvement of fluorine-18 fluorodeoxyglucose position emission tomography (FDG-PET) on outcome and chemo-sensitivity in hepatocellular carcinoma patients
P-142 Accuracy of MRI imaging for the detection of hepatocellular carcinoma in patients with cirrhosis: correlation with the whole explanted liver
P-143 Enhancement patterns of hepatocellular carcinoma on contrast-enhanced ultrasound: comparison with histologic differentiation
P-144 Changes in enhancement and morphology on CT imaging in hepatocellular carcinoma treated with Bevacizumab and Erlotinib
P-145 Toronto hepatobiliary carcinoma screening protocol (TSHSP): analysis of 3 modality approach to workup of small or indeterminate lesions detected at screening for HCC
P-146 Delayed hepatoc Archie of arterially-enhancing nodules in cirrhotic livers for diagnosis of hepatocellular carcinoma
P-147 Irregol regereation in a diffuse finding possibly related to hepatocellular carcinoma in hepatitis C cirrhosis
P-148 Small nodules (10-20 mm) in liver cirrhosis: characterization with contrast-enhanced ultrasound
P-149 Haemodynamic analysis of small hepatic lymphoid tumours with angioscopy assisted CT
P-150 Imaging of benign hepatic neoplasms in alcoholic liver cirrhosis: differentiation from hypercellular hepatocellular carcinoma
P-151 Hepato-cellular carcinoma-induced in familial non-alcoholic steatohepatitis
P-152 Somatostatin receptors (SSTR) screening in hepatobiliary carcinoma (HCC): comparison between Octreoscan® and Neopect®: a pilot study
P-153 18FDG monoclonal antibody as a promising tissue marker for hepatocellular carcinoma. Is the radiologic stage according with the pathologic stage in liver transplantation?
P-155 Prospective validation of AASL guidelines for the early diagnosis of hepatocellular carcinoma in cirrhotic patients

4. Clinical trials and treatment research
P-156 Treatment of hepatocellular carcinoma by radiofrequency-thermal ablation versus transcatheter arterial chemoembolization with or without subcutaneous viscum (Fralarin) injection
P-157 A3 adenosine receptor expression and functionality in hepatocellular carcinoma: involvement of m-kappa b
P-158 Epidemiology and outcome of hepatocellular carcinoma in Lombardy. A population-based study
P-159 Chemotherapy could be a therapeutic option for hepatocellular carcinoma (HCC) in patients with non-cirrhotic liver
P-160 Adjuvant intra-arterial injection of 18F-fluorodeoxyglucose labeled lipiodol after resection of hepatocellular carcinoma: progress report of a case – control study with a 5 years minimal follow-up
P-161 Preliminary results of “metronomic” capcitabine treatment in advanced hepatocellular carcinoma (HCC)
P-162 Preliminary results of “metronomic” capcitabine treatment in advanced epatocellular carcinoma (HCC)
P-163 Phase II trial of continuous hepatic arterial infusion (HAI) of irinotecan in patients with hepatocellular carcinoma (HCC)
P-164 Three radiofrequency systems for non-small hepatocellular carcinoma: comparative technique effectiveness after one session
P-165 Toxicity of HCC with occlusin/BD and doxorubicin: phase I results of a new embolic agent
P-166 Hepatoblastoma in patients aged 10-18 years. Report from the international childhood liver tumor strategy group (SIOP/PEL)
P-167 Arterial chemoembolization pre-treatment in HCC. Is it useful?
P-168 Recurrence of hepatocellular carcinoma after liver transplantation
P-169 Liver transplantation after bipapnic liver resection for hepatocellular carcinoma
P-170 What is the best staging system to predict the survival after curative resection for hepatocellular carcinoma?
P-171 Single-agent penetrexed does not appear to benefit patients with advanced hepatoma in the community setting
P-172 Phase II study of amplitude-modulated electromagnetic fields in the treatment of advanced hepatocellular carcinoma
P-173 Liver transplantation for hepatocellular carcinoma: validation of a new prognostic score predicting disease-free survival
P-174 Moderate expansion of Milan criteria for transplantation for HCC does not impact survival nor recurrence rates
P-175 Thymostimulin in advanced hepatocellular carcinoma: a phase II trial
P-176 Time-to-progression as a parameter for evaluating the therapeutic effects of transcatheter arterial chemoembolization in patients with advanced hepatocellular carcinoma
P-177 Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma
P-178 Gemcitabine-based transarterial chemoembolization (TACE) for unresectable cholangiocarcinoma
P-179 Right hepatic lobectomy using the staple technique in 101 patients
P-180 LY2109761 as a potential drug for HCC. A preclinical study
P-181 Liver transplantation for hepatocellular carcinoma: a new policy on selection criteria and organ allocation
P-182 Re-evaluation of the Milan criteria for liver transplantation in patients with hepatocellular carcinoma
P-184 Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma
P-185 Liver transplantation in hepatocellular carcinoma across Milan criteria
P-186 Phase I and pharmacokinetic study of S-1 for advanced hepatocellular carcinoma: impact of liver disorder
P-187 Prospective study on hepatocellular carcinoma, epidemiological, clinical characteristics and results of treatment
P-188 Phase II trial to assess the safety/toxicity/pharmakokinetics of MB07133 in subjects with unresectable hepatocellular carcinoma
P-189 Radioembolization of advanced hepatocellular carcinoma using 90y-resin microspheres in significant control of local tumor growth
P-190 Efficacy of interventional radiology therapies in hepatocellular carcinoma assessed by local response and survival
P-191 The effect of hepatic arterial infusion therapy for PVT in the advanced HCC
P-192 Stabilization of disease after repeated intrahepatic infusion of ocdytotic herpes simplex virus NV1020 prior to 2nd-line chemotherapy with CPT-11 + and cetuximab in a patient with progressive colorectal cancer metastatic to the liver
P-193 Phase II study of 4-fraction carbon ion radiotherapy for hepatocellular carcinoma
P-194 Efficacy of hepatic resection after preoperative combined transarterial chemotherapy and radiation therapy in hepatocellular carcinoma more than 5 cm in size
5. Miscellaneous

P-240 Differential expression of Sti1-Robo genes in cells derived from hepatocellular carcinoma

P-241 Possible regression of Danazol induced-hepatocellular tumours after stopping treatment

P-242 The proteasome inhibitor Bortezomib and oncolytic virotherapy act synergistically in hepatocellular carcinoma

P-243 A quantitative proteomic approach for identification of biomarkers in hepatocellular carcinoma

P-244 Laparoscopic liver resection for hepatocellular carcinoma (HCC) complicating chronic liver disease

P-245 Validation study of the prognostic immunohistochemical marker glypican-3 in hepatocellular carcinoma

P-246 Blood telomerase activity and DNA telicentric properties in human hepatocellular carcinoma and chronic liver disease

P-247 Laparoscopic cholecystectomy in the cirrhotic patient

P-248 The conditionally replicating adenovirus ad536 sensor replicates selectively in p53-altered tumour cells and potential tumour spectrum is not limited by the p73 status

P-249 Pattern of care study on radiotherapy for locally advanced hepatocellular carcinoma

P-250 Combined chemoradiotherapy and percutaneous radiofrequency ablation for local control of liver tumors

P-251 Efficacy and tolerance of multipolar radiofrequency ablation for the treatment of large HCC: larger than 5 cm

P-252 The conditionally replicating adenovirus ad536 sensor replicates selectively in p53-altered tumour cells and potential tumour spectrum is not limited by the p73 status

P-253 Dosimetric comparison of 3D-conformal radiotherapy, intensity modulated radiotherapy, and helical tomotherapy for hepatocellular carcinoma

P-254 Drop-out rates in patients with hepatocellular carcinoma within Milan's criteria waiting for liver transplantation

P-255 The impact of small-for-size syndrome on tumour recurrence after LDLT for HCC

P-256 Phase 2 validation study comparing des-gamma-carboxy prothrombin (DCP), total-alpha-fetoprotein (AFP) and APF-L3

P-257 Tumour recurrence following liver transplantation for hepatocellular carcinoma: role of tumour proliferation status

P-258 Liver stiffness measurements in patients with cirrhosis and hepatocellular carcinoma: a case-control study

P-259 Cortistatin, proinflammatory cytokines, ethanol and acetaldehyde as possible mechanisms of hepatocellular carcinoma resistance to octreotide

P-260 Telomerase-dependent conditionally replicating adenovirus expressing CARex-PTDs displays enhanced oncolytic properties in CAR-deficient tumors

P-261 Increased age does not imply in higher HCC patients mortality in a referral tertiary hospital

P-262 Immediate cytological diagnosis of primary malignant liver tumors

P-263 SULF1 - A novel oncogenic protein in hepatocellular carcinoma (HCC)

P-264 Proteomic identification in plasma of new molecular markers for hepatocellular carcinoma

P-265 Differential expression of hepatitis B virus x antigen in tumour and adjacent non-tumour hepatocytes in hepatitis B related hepatocellular carcinoma

P-266 The development of a swine model of secondary liver tumours from a genetically induced swine fibrolasts cell line

P-267 The relation ship between indocyanine green test and portal venous pressure

P-268 Cu mal? A decision analysis of expanding Milan criteria for liver transplantation of hepatocellular carcinoma

P-269 The hepatoblastoma tumour family: a novel concept based on the SIOPEL experience

P-270 Do patients with hepatocellular carcinoma and hepatitis C have worse or better outcome after liver transplantation than patients with hepatitis C alone?

P-271 Induction of immunosuppressive molecules counteract the antitumor effect of interleukin-12-based gene therapy in a transgenic mouse model of liver cancer

P-272 Child's A patients with small hepatocellular carcinoma within Milan criteria: resection or transplant?
Industry Symposium Highlights

Friday, 5 October

11.30 - 13.15  Industry Symposium (Biocompatibles)
TACE in HCC: A multi-disciplinary overview
Chair: Jordi Bruix, Barcelona (Spain)

- The scientific rationale for TACE and health/safety considerations
  Irene Krämer, Mainz (Germany)
- An overview of the clinical data
  Josep M. Llovet, Barcelona (Spain) - New York (USA)
- Device selection and delivery technique
  Riccardo Lencioni, Pisa (Italy)
- Oncology perspectives on the management of liver cancer
  Michel Ducreux, Villejuif (France)

Lunch will be provided prior to the Biocompatibles symposium.

18.00 - 19.30  Industry Symposium (Bayer Schering Pharma)
Recent advances with targeted therapies: a new era in the management of hepatocellular carcinoma
Chair: Jordi Bruix, Barcelona (Spain)

- Welcome and introduction
  Jordi Bruix, Barcelona (Spain)
- Hepatocellular carcinoma: current approaches to management
  Jordi Bruix, Barcelona (Spain)
- Targeting the underlying molecular mechanisms of hepatocellular carcinoma
  Gregory J. Gores, Rochester (USA)
- Management of hepatocellular carcinoma: recent advances and future prospects
  Josep M. Llovet, Barcelona (Spain) - New York (USA)
- Discussion and concluding remarks

Refreshments will be provided.
Saturday, 6 October

13.00 - 15.00 Industry Symposium (Bracco)
Focal liver lesions - The key role of contrast-enhanced UltraSound (CEUS) modality for diagnosis and early assessment of treatment efficacy

Chair: Riccardo Lencioni, Pisa (Italy)

- Clinical guidelines - The consensus opinion of experts as regard to the role of CEUS modality in liver imaging
  Riccardo Lencioni, Pisa (Italy)
- STIC study for focal liver lesion diagnosis – Take-home messages from a large multicenter clinical trial using CEUS in comparison to MDCT and CEMRI
  François Tranquart, Tours (France)
- The use of CEUS during liver surgery – Its impact on operative outcome
  Guido Torzilli, Milan (Italy)

A light lunch will be provided.
The International Liver Cancer Association (ILCA) aspires towards advancing research in the pathogenesis, prevention, and treatment of liver cancer.

► Mission
The International Liver Cancer Association (ILCA) promotes novel pathogenic, diagnostic and therapeutic interventions for liver cancer by taking a transversal approach to research and bringing together scientists, physicians and allied professionals from all interrelated fields.

► Values
The International Liver Cancer Association (ILCA):
- Is committed to promoting basic, clinical, translational, multi-disciplinary and multi-national liver cancer research, including the development of clinical trials
- Fosters, encourages and facilitates scientific exchange and dissemination of knowledge
- Strives to educate physicians, scientists, allied healthcare professionals and the general public at large
- Will educate international and national health authorities on the diagnosis, prevention and management of liver cancer
- Values collaboration with other learned societies, governmental organizations, professional associations, groups, institutions and individuals who contribute to progress in the field.

ILCA is the only international organization devoted exclusively to liver cancer research for experts from all related disciplines.

ILCA’s Interim Governing Board

Executive Committee
President
Jordi Bruix (Spain)
Executive Secretary
Josep M Llovet (Spain/USA)
Treasurer
Peter Galle (Germany)

Council
Nelson Fausto (USA)
Snorri Thorgeirsson (USA)
Riccardo Lencioni (Italy)
Pierre-Alain Clavien (Switzerland)
Vincenzo Mazzaferro (Italy)
Masamichi Kojiro (Japan)

Contact Us
International Liver Cancer Association (ILCA)
Global Headquarters
Avenue de Tervueren, 300
B-1150 Brussels – Belgium
Tel: +32 (0)2 789-2345
Fax: +32 (0)2 743-1550
Email: info@ilca-online.org
www.ilca-online.org
PLEASE MAIL OR FAX THE COMPLETED FORM AND SUPPORTING MATERIALS TO:
International Liver Cancer Association (ILCA) - Attn: Francesca Rollo
Global Headquarters - Avenue de Tervueren 300 - B-1150 Brussels - Belgium
Tel: +32-2-743 4447 - Fax: +32-2-743 1550
Email: membership@ilca-online.org

TO LEARN MORE ABOUT ILCA VISIT:
www.ilca-online.org

PLEASE COMPLETE THE APPLICATION FORM IN CAPITAL LETTERS.

PERSONAL DETAILS [Please complete all sections]
Name ................................................................. | ................................................................. | ................................................................. | ................................................................. |
Position ................................................................. | Institution ................................................................. |
Street / Box # ................................................................. | City ................................................................. |
Zip / Postal Code ................................................................. | State / Province ................................................................. |
Tel. ........................................................................... | Fax ......................................................................... |
Email ........................................................................... |
Web Site ........................................................................... | Date of Birth (month/date/year) ______ / ______ / ______ |

Applicant’s Signature

PROFESSIONAL ACTIVITY [Please check ✔ all that apply]

Administrator ................................................................. □
Allied Health Professional ................................................................. □
Basic Researcher ................................................................. □
Clinical Practitioner ................................................................. □
Clinical Researcher ................................................................. □
Industry Representative ................................................................. □
Retired ........................................................................... □
Teacher/Educator ........................................................................... □
Trainee ........................................................................... □

DISCIPLINE INTEREST [Please check ✔ all that apply]

Basic Research ................................................................. □
Clinical Research ................................................................. □
Epidemiology ................................................................. □
Gastroenterology ................................................................. □
Hepatology ........................................................................... □
Internal Medicine ........................................................................... □
Molecular Biology ........................................................................... □
Oncology ........................................................................... □
Pathology ........................................................................... □
Radiology/Interventional Oncology ................................................................. □
Surgery/Transplantation ........................................................................... □
Other (please specify) ........................................................................... □

PRIMARY PRACTICE / RESEARCH SETTING [Please check ✔ all that apply]

Clinical Research/Practice ................................................................. □
Academic Institution/University ................................................................. □
Private Practice ........................................................................... □
Private Institution ........................................................................... □
Public Institution/Agency ........................................................................... □
Government Institution/Agency ........................................................................... □

MEMBER CATEGORY, FEES & SUPPORTING DOCUMENTS [membership valid for the calendar year 1 January to 31 December 2007]

Regular □ Fee: 50 Euro (scientist / physician working in fields related to liver cancer who has contributed knowledge to the field).
• Please provide these supporting documents:
  ▪ Letter of support from Founding Member
  ▪ Proof of publication of at least 2 papers with an Impact Factor according to the last ISI Web of Knowledge

Trainee □ Fee: 25 Euro (scientist / physician in training and certified by his/her training program director).
• Please provide these supporting documents:
  ▪ Letter of support from training program director or a Founding Member

Associate □ Fee: 25 Euro (allied health professionals involved in liver cancer research and/or practice).
• Please provide these supporting documents:
  ▪ Brief bio-sketch
  ▪ Letter of support from a Founding Member
  ▪ Statement of commitment to liver cancer research/practice

Emeritus □ Fee: 50 Euro (scientist / physician meeting Regular member requirements, but who is retired from full-time employment).
• Please provide these supporting documents:
  ▪ Brief bio-sketch
  ▪ Proof of publication of at least 2 papers with an Impact Factor

Voluntary Donation [to ILCA for the development of its professional activities] □ Amount: ................. Euro

METHOD OF PAYMENT [Please check ✔ and provide all information requested]

Wire Transfer

To the attention of MCI Benelux/ILCA
Account#: 363-0098456-41
IBAN#: BE88 363 0098456 41
BIC/Swift#: BBRUBEBB

Check Number ___________ DATED (month/day/year) ______ / ______ / ______

Membership fee ____________________________ + processing fee ____________

Credit Card □ American Express □ MasterCard □ Visa

Card Number ____________________________

Expire ______ / ______ Name of Card Holder (as it appears on the card) ____________________________

Signature of Card Holder ____________________________